Medical release archive

AstraZeneca receives approval in the EU for Qtern (saxagliptin and dapagliflozin) for treatment of type-2 diabetes

Durvalumab monotherapy demonstrates efficacy in urothelial bladder cancer

AstraZeneca to present anifrolumab lupus data at Annual European Congress of Rheumatology (EULAR 2016)

Tagrisso (osimertinib) shows clinical activity in patients with leptomeningeal disease from lung cancer

Lynparza (olaparib): latest data suggest potential overall survival advantage in patients with platinum sensitive ovarian cancer

Positive CHMP opinion in EU for saxa/dapa (saxagliptin and dapagliflozin) for adults with type-2 diabetes

SOCRATES trial results for Brilinta/Brilique presented at European Stroke Organisation Conference

AstraZeneca presents positive Tagrisso (osimertinib) follow-up data in lung cancer at ELCC 2016

acalabrutinib recommended for orphan drug designation in Europe for three indications

AstraZeneca’s combination of durvalumab with tremelimumab shows clinical activity in non-small cell lung cancer irrespective of PD-L1 status